FDA Panel Backs Unproven Peptides, Including 'Wolverine Stack'
An advisory panel of outside experts has recommended that the U.S. Food and Drug Administration (FDA) add several unproven peptides to its bulk list. This list is often used by compounding pharmacies to create custom medications. Notably, the panel endorsed the inclusion of the "Wolverine stack," a combination of peptides popularized by podcast host Joe Rogan and other social media influencers. Some of these experts have financial ties to the peptide industry, raising questions about potential conflicts of interest. The recommendation does not constitute FDA approval but rather a suggestion for inclusion on a list used for compounding purposes. The substances in question have not undergone the rigorous clinical trials typically required for FDA approval of new drugs. This decision could lead to wider availability of these peptides through compounding pharmacies, despite their unproven efficacy and safety profiles.
The FDA panel's endorsement of unproven peptides, including those promoted by influencers, highlights a tension between regulatory oversight and the burgeoning market for performance-enhancing and wellness supplements. The inclusion of substances on the bulk list, especially when some panelists have financial interests, warrants scrutiny of the review process and potential conflicts of interest. This situation reflects broader challenges in regulating novel compounds that gain traction through social media and influencer marketing before robust scientific validation. As the wellness and biohacking industries continue to evolve, clear guidelines and transparent review mechanisms are crucial to balance innovation with public health and safety, ensuring that consumers have access to evidence-based treatments rather than speculative compounds.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.